

CITATION REPORT

List of articles citing

Pharmacokinetics and Disposition of Carvedilol in Humans

DOI: 10.1097/00005344-198710004-00015

Journal of Cardiovascular Pharmacology, 1987, 10, S85-S88.

Source: <https://exaly.com/paper-pdf/18766357/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
77	Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. <i>European Journal of Clinical Pharmacology</i> , 1990 , 38 Suppl 2, S108-11	2.8	85
76	The use of carvedilol in elderly hypertensive patients. <i>European Journal of Clinical Pharmacology</i> , 1990 , 38 Suppl 2, S129-33	2.8	10
75	The safety of adding carvedilol to hypertensive patients inadequately treated with diuretics. <i>European Journal of Clinical Pharmacology</i> , 1990 , 38 Suppl 2, S153-7	2.8	7
74	Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial. <i>European Journal of Clinical Pharmacology</i> , 1990 , 38 Suppl 2, S158-63	2.8	8
73	Identification of two major biliary metabolites of carvedilol in rats. <i>Xenobiotica</i> , 1990 , 20, 1025-34	2	12
72	Neuroprotective effects of carvedilol, a new antihypertensive, at the N-methyl-D-aspartate receptor. <i>Neuroscience Letters</i> , 1992 , 148, 34-8	3.3	23
71	Carvedilol: A Novel Cardiovascular Drug with Multiple Actions. <i>Cardiovascular Drug Reviews</i> , 1992 , 10, 127-157		55
70	Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure. <i>European Journal of Clinical Pharmacology</i> , 1992 , 43, 85-8	2.8	18
69	Rats with portacaval shunt as a potential experimental pharmacokinetic model for liver cirrhosis: application to carvedilol stereopharmacokinetics. <i>Chirality</i> , 1993 , 5, 1-7	2.1	7
68	Saturable enantioselective first-pass effect for carvedilol after high oral racemate doses in rats. <i>Archiv Der Pharmazie</i> , 1993 , 326, 123-5	4.3	6
67	Carvedilol stereopharmacokinetics in rats: affinities to blood constituents and tissues. <i>Archiv Der Pharmazie</i> , 1993 , 326, 529-33	4.3	20
66	Lack of a pharmacokinetic interaction between carvedilol and digitoxin or phenprocoumon. <i>European Journal of Clinical Pharmacology</i> , 1993 , 44, 583-6	2.8	4
65	SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant. <i>European Journal of Pharmacology</i> , 1994 , 251, 237-43	5.3	55
64	Neuroprotective effects of carvedilol, a new antihypertensive, as a Na ⁺ channel modulator and glutamate transport inhibitor. <i>Neuroscience Letters</i> , 1994 , 171, 77-80	3.3	20
63	The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man. <i>British Journal of Clinical Pharmacology</i> , 1995 , 40, 19-23	3.8	15
62	Neuroprotective activities of carvedilol and a hydroxylated derivative: role of membrane biophysical interactions. <i>Biochemical Pharmacology</i> , 1998 , 56, 1645-56	6	31
61	Carvedilol. <i>New England Journal of Medicine</i> , 1998 , 339, 1759-65	59.2	208

60	Clinical Pharmacology of Carvedilol. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1999 , 4, 205-218	2.6	23
59	Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs. <i>American Journal of Veterinary Research</i> , 2000 , 61, 57-60	1.1	16
58	Inhibition of heart mitochondrial lipid peroxidation by non-toxic concentrations of carvedilol and its analog BM-910228. <i>Biochemical Pharmacology</i> , 2001 , 61, 155-64	6	21
57	Antioxidants and prevention of restenosis after directional coronary atherectomy. <i>Circulation</i> , 2001 , 103, E51-2	16.7	3
56	Differential effects of short and prolonged exposure to carvedilol on voltage-dependent Na(+) channels in cultured bovine adrenal medullary cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 302, 212-8	4.7	29
55	Carvedilol inhibits platelet-derived growth factor-induced signal transduction in human cardiac fibroblasts. <i>Journal of Cardiovascular Pharmacology</i> , 2002 , 39, 576-89	3.1	10
54	Cardiovascular and renal effects of carvedilol in dogs with heart failure. <i>Journal of Veterinary Medical Science</i> , 2002 , 64, 469-75	1.1	21
53	Novel effect of carvedilol on Ca ²⁺ movement in renal tubular cells. <i>Biochemical Pharmacology</i> , 2002 , 64, 1777-84	6	7
52	Comparison between a sustained administration of carvedilol versus atenolol to reduce restenosis after coronary stenting. <i>American Heart Journal</i> , 2004 , 147, E7	4.9	4
51	Carvedilol: a new candidate for reversal of MDR1/P-glycoprotein-mediated multidrug resistance. <i>Anti-Cancer Drugs</i> , 2004 , 15, 303-9	2.4	16
50	Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers. <i>Biological and Pharmaceutical Bulletin</i> , 2005 , 28, 1476-9	2.3	38
49	Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model. <i>Circulation Journal</i> , 2005 , 69, 101-6	2.9	30
48	Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. <i>Drug Development and Industrial Pharmacy</i> , 2005 , 31, 785-94	3.6	128
47	Cytoprotective effects of carvedilol against oxygen free radical generation in rat liver. <i>Redox Report</i> , 2005 , 10, 131-7	5.9	18
46	Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs. <i>American Journal of Veterinary Research</i> , 2005 , 66, 2172-6	1.1	15
45	Pharmacodynamics of Carvedilol in Conscious, Healthy Dogs. <i>Journal of Veterinary Internal Medicine</i> , 2006 , 20, 297-304	3.1	11
44	Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers. <i>Biological and Pharmaceutical Bulletin</i> , 2006 , 29, 772-8	2.3	42
43	Stereoselective metabolism of carvedilol by the beta-naphthoflavone-inducible enzyme in human intestinal epithelial Caco-2 cells. <i>Biological and Pharmaceutical Bulletin</i> , 2007 , 30, 1930-3	2.3	6

42	Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity. <i>Biological and Pharmaceutical Bulletin</i> , 2007 , 30, 2146-53	2.3	26
41	Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis. <i>Biological and Pharmaceutical Bulletin</i> , 2007 , 30, 537-42	2.3	34
40	What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. <i>Drug Metabolism Reviews</i> , 2007 , 39, 17-43	7	173
39	Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , 2007 , 16, 612-9	2.6	46
38	Stereoselective glucuronidation of carvedilol by Chinese liver microsomes. <i>Journal of Zhejiang University: Science B</i> , 2007 , 8, 756-64	4.5	2
37	Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. <i>British Journal of Clinical Pharmacology</i> , 2008 , 65, 511-22	3.8	46
36	Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2008 , 13, 51-7	2.6	18
35	Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes. <i>Biological and Pharmaceutical Bulletin</i> , 2008 , 31, 1297-300	2.3	26
34	Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure. <i>Biological and Pharmaceutical Bulletin</i> , 2008 , 31, 976-80	2.3	21
33	Development and characterization of a carvedilol-loaded self-microemulsifying delivery system. <i>Clinical Research and Regulatory Affairs</i> , 2009 , 26, 50-64		10
32	Involvement of the CYP1A subfamily in stereoselective metabolism of carvedilol in beta-naphthoflavone-treated Caco-2 cells. <i>Biological and Pharmaceutical Bulletin</i> , 2009 , 32, 513-6	2.3	11
31	Inhibitory and stimulative effects of amiodarone on metabolism of carvedilol in human liver microsomes. <i>Biological and Pharmaceutical Bulletin</i> , 2010 , 33, 717-20	2.3	4
30	The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010 , 15, 373-9	2.6	16
29	Clinical updates on carvedilol: a first choice beta-blocker in the treatment of cardiovascular diseases. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010 , 6, 237-50	5.5	13
28	Treatment of carvedilol for refractory hypertension in patients with renal diseases: A multicentre, prospective clinical trial. <i>Biomedicine and Aging Pathology</i> , 2011 , 1, 203-209		1
27	The fate of 4-hydroxycarbazole metabolite: metabolism and carcinogenicity assessment of a β adrenergic receptor modulator containing carbazole structure. <i>Xenobiotica</i> , 2011 , 41, 1108-21	2	1
26	Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca ²⁺ release. <i>Nature Medicine</i> , 2011 , 17, 1003-9	50.5	157
25	Why do metabolites circulate?. <i>Xenobiotica</i> , 2012 , 42, 107-26	2	31

24	Stereoselective glucuronidation of carvedilol in human liver and intestinal microsomes. <i>Pharmacology</i> , 2012 , 90, 117-24	2.3	5
23	ADME of Cardiovascular Drugs. 2012 , 1		
22	Microemulsions for oral administration and their therapeutic applications. <i>Expert Opinion on Drug Delivery</i> , 2012 , 9, 937-51	8	42
21	Effects of myricetin on the bioavailability of carvedilol in rats. <i>Pharmaceutical Biology</i> , 2012 , 50, 516-22	3.8	12
20	Carvedilol blocks the cloned cardiac Kv1.5 channels in a β -adrenergic receptor-independent manner. <i>Biochemical Pharmacology</i> , 2012 , 83, 497-505	6	9
19	Carvedilol. <i>Profiles of Drug Substances, Excipients and Related Methodology</i> , 2013 , 38, 113-57	3	21
18	Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2014 , 39, 53-9	2.7	
17	Non- β -blocking R-carvedilol enantiomer suppresses Ca^{2+} waves and stress-induced ventricular tachyarrhythmia without lowering heart rate or blood pressure. <i>Biochemical Journal</i> , 2015 , 470, 233-42	3.8	24
16	A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 943-62	6.2	32
15	Transcriptional profiling of reactive metabolites for elucidating toxicological mechanisms: a case study of quinoneimine-forming agents. <i>Drug Metabolism Reviews</i> , 2015 , 47, 45-55	7	4
14	Simultaneous quantification of carvedilol and its metabolites in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and pharmacokinetic application. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015 , 974, 138-46	3.2	7
13	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. <i>Drug Metabolism and Pharmacokinetics</i> , 2016 , 31, 425-432	2.2	1
12	In Vitro Enhancement of Carvedilol Glucuronidation by Amiodarone-Mediated Altered Protein Binding in Incubation Mixture of Human Liver Microsomes with Bovine Serum Albumin. <i>Biological and Pharmaceutical Bulletin</i> , 2016 , 39, 1359-63	2.3	
11	Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016 , 1015, 173-180	3.2	6
10	Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017 , 42, 383-396	2.7	21
9	Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 760-769	2.9	2
8	Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. <i>European Journal of Pharmaceutical Sciences</i> , 2017 , 109S, S108-S115	5.1	7
7	Involvement of alpha- and beta-adrenoceptors in the automaticity of the isolated guinea pig pulmonary vein myocardium. <i>Journal of Pharmacological Sciences</i> , 2017 , 133, 247-253	3.7	11

6	Integration of in vitro biorelevant dissolution and in silico PBPK model of carvedilol to predict bioequivalence of oral drug products. <i>European Journal of Pharmaceutical Sciences</i> , 2018 , 118, 176-182	5.1	8
5	Characterization and molecular basis for the block of Kv1.3 channels induced by carvedilol in HEK293 cells. <i>European Journal of Pharmacology</i> , 2018 , 834, 206-212	5.3	1
4	Carvedilol blockage of delayed rectifier Kv2.1 channels and its molecular basis. <i>European Journal of Pharmacology</i> , 2019 , 855, 50-55	5.3	1
3	Drugs Acting on Multiple Receptors: Blockers with Additional Properties. <i>Handbook of Experimental Pharmacology</i> , 1990 , 131-226	3.2	4
2	A comparison of carvedilol and metoprolol antioxidant activities in vitro. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 36, 277-81	3.1	50
1	Preparation and Dissolution Properties of Oral Controlled Release Formulation Containing Carvedilol. <i>Journal of the Korea Academia-Industrial Cooperation Society</i> , 2010 , 11, 2451-2458		